Nuvo Research Inc. (NRI.TO) 3.00 $NRI.TO
Nuvo Research® closes $3.1 million private placement
CNW Group - Tue Apr 01, 6:30AM CDT
Nuvo Research Inc. (TSX:NRI), (the "Company"
, a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, is pleased to announce the closing of a non-brokered private placement (the "Private Placement", pursuant to which an aggregate of 1,390,000 units of the Company were issued at a price of $2.25 per unit, raising gross proceeds of approximately $3,127,500. Each Unit consists of one common share of the Company and one-half of one common share purchase warrant of the Company. Each whole warrant entitles the holder to purchase one common share of the Company at a price of $3.00 for a 24-month period, subject to acceleration at the option of the Company in the event that the ten-day volume weighted share price for the Company's common shares is equal to or exceeds $3.50 on the Toronto Stock Exchange ("TSX" at any time during the warrant term. First Republic Capital Corporation ("First Republic" was the primary finder of the participants in the offering.
Nuvo Research announces 2013 fourth quarter & year-end results
CNW Group - Thu Feb 20, 4:00PM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced its financial and operational results for the fourth quarter and year ended December 31, 2013.
Nuvo Research Announces the U.S. Commercial Launch of PENNSAID® 2% by Mallinckrodt
CNW Group - Mon Feb 10, 7:00AM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced the U.S. commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) by its U.S. commercial licensee Mallinckrodt (NYSE:MNK). PENNSAID 2% is the first twice per day topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the United States for the treatment of the pain of osteoarthritis of the knee(s). Nuvo receives royalties on U.S. sales of PENNSAID 2%.
Chrysler Group Reports Full-Year 2013 Net Income of $2.8 Billion, Including a $962 Million Non-Cash Tax Benefit
PR Newswire - Wed Jan 29, 4:26AM CST
-- Chrysler Group LLC's full-year net income was $2.8 billion, including a $962 million non-cash tax benefit related to the release of valuation allowances on deferred tax assets; full-year 2012 net income was $1.7 billion
Nuvo Research Announces FDA Approval of PENNSAID® 2%
CNW Group - Fri Jan 17, 6:00AM CST
- Mallinckrodt to Launch PENNSAID 2% in the U.S. in Q1 2014 -
Nuvo Research(R) and NovaMedica Sign Agreement to Market Pennsaid(R) in Russia
Business Wire - Thu Dec 19, 6:30AM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States (CIS).
Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia
CNW Group - Thu Dec 19, 6:30AM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States (CIS).
Nuvo Research Announces 2013 Third Quarter Results
CNW Group - Wed Oct 30, 4:00PM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the third quarter ended September 30, 2013.
Nuvo Research® Announces Scientific Presentations at Annual Painweek 2013 Meeting
PR Newswire - Thu Sep 05, 6:30AM CDT
Data Evaluating Heated Lidocaine/Tetracaine Patch for the Treatment of Acute Musculoskeletal Pain to be Presented
Nuvo Research® announces that FDA has accepted Pennsaid® 2% new drug application for review
CNW Group - Thu Aug 22, 6:30AM CDT
Nuvo Research Inc. (Nuvo) (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID(® )(diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt (NYSE:MNK) has advised that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013. The FDA has indicated to Mallinckrodt that it expects to respond to the NDA by February 7, 2014.
Nuvo Research® announces lawsuit against Mallinckrodt
CNW Group - Wed Aug 21, 6:30AM CDT
Nuvo Research Inc. (Nuvo) (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that the Company has commenced legal action against Mallinckrodt Inc. (Mallinckrodt) by filing a Complaint in the United States District Court for the Southern District of New York.
Nuvo Research® closes $3.1 million private placement
CNW Group - Tue Apr 01, 6:30AM CDT
Nuvo Research Inc. (TSX:NRI), (the "Company"
, a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, is pleased to announce the closing of a non-brokered private placement (the "Private Placement", pursuant to which an aggregate of 1,390,000 units of the Company were issued at a price of $2.25 per unit, raising gross proceeds of approximately $3,127,500. Each Unit consists of one common share of the Company and one-half of one common share purchase warrant of the Company. Each whole warrant entitles the holder to purchase one common share of the Company at a price of $3.00 for a 24-month period, subject to acceleration at the option of the Company in the event that the ten-day volume weighted share price for the Company's common shares is equal to or exceeds $3.50 on the Toronto Stock Exchange ("TSX" at any time during the warrant term. First Republic Capital Corporation ("First Republic" was the primary finder of the participants in the offering. Nuvo Research announces 2013 fourth quarter & year-end results
CNW Group - Thu Feb 20, 4:00PM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced its financial and operational results for the fourth quarter and year ended December 31, 2013.
Nuvo Research Announces the U.S. Commercial Launch of PENNSAID® 2% by Mallinckrodt
CNW Group - Mon Feb 10, 7:00AM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced the U.S. commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) by its U.S. commercial licensee Mallinckrodt (NYSE:MNK). PENNSAID 2% is the first twice per day topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the United States for the treatment of the pain of osteoarthritis of the knee(s). Nuvo receives royalties on U.S. sales of PENNSAID 2%.
Chrysler Group Reports Full-Year 2013 Net Income of $2.8 Billion, Including a $962 Million Non-Cash Tax Benefit
PR Newswire - Wed Jan 29, 4:26AM CST
-- Chrysler Group LLC's full-year net income was $2.8 billion, including a $962 million non-cash tax benefit related to the release of valuation allowances on deferred tax assets; full-year 2012 net income was $1.7 billion
Nuvo Research Announces FDA Approval of PENNSAID® 2%
CNW Group - Fri Jan 17, 6:00AM CST
- Mallinckrodt to Launch PENNSAID 2% in the U.S. in Q1 2014 -
Nuvo Research(R) and NovaMedica Sign Agreement to Market Pennsaid(R) in Russia
Business Wire - Thu Dec 19, 6:30AM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States (CIS).
Nuvo Research® and NovaMedica sign agreement to market Pennsaid® in Russia
CNW Group - Thu Dec 19, 6:30AM CST
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC (NovaMedica), a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States (CIS).
Nuvo Research Announces 2013 Third Quarter Results
CNW Group - Wed Oct 30, 4:00PM CDT
Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the third quarter ended September 30, 2013.
Nuvo Research® Announces Scientific Presentations at Annual Painweek 2013 Meeting
PR Newswire - Thu Sep 05, 6:30AM CDT
Data Evaluating Heated Lidocaine/Tetracaine Patch for the Treatment of Acute Musculoskeletal Pain to be Presented
Nuvo Research® announces that FDA has accepted Pennsaid® 2% new drug application for review
CNW Group - Thu Aug 22, 6:30AM CDT
Nuvo Research Inc. (Nuvo) (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID(® )(diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt (NYSE:MNK) has advised that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013. The FDA has indicated to Mallinckrodt that it expects to respond to the NDA by February 7, 2014.
Nuvo Research® announces lawsuit against Mallinckrodt
CNW Group - Wed Aug 21, 6:30AM CDT
Nuvo Research Inc. (Nuvo) (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that the Company has commenced legal action against Mallinckrodt Inc. (Mallinckrodt) by filing a Complaint in the United States District Court for the Southern District of New York.
